CRESCENT BIOPHARMA, INC. (CBIO) Operating cash flow 2016–2025
CRESCENT BIOPHARMA, INC. (CBIO) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$71.5MFY2025 · since FY2016: -$29.7M → -$71.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$71.5M | -130.0% |
| FY2024 | -$31.1M | +10.8% |
| FY2023 | -$34.9M | +24.9% |
| FY2022 | -$46.5M | +19.2% |
| FY2021 | -$57.5M | -46.5% |
| FY2020 | -$39.2M | +24.5% |
| FY2019 | -$52.0M | -20.0% |
| FY2018 | -$43.3M | -45.6% |
| FY2017 | -$29.8M | -0.1% |
| FY2016 | -$29.7M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More CBIO financial trends
CBIO RevenueCBIO Net incomeCBIO Net marginCBIO Gross profitCBIO Gross marginCBIO Operating incomeCBIO Operating marginCBIO Free cash flowCBIO Capital expendituresCBIO Return on equityCBIO Stock buybacksCBIO Dividends paidCBIO Total assetsCBIO Total liabilitiesCBIO Shareholders’ equityCBIO overview →